rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Traws Pharma, Inc.

TRAW · Nasdaq

Health CareBiotechnologyNot moving yet

TRAW stood above a rising 150-day average in 11 of the last 52 weekly readings, and has been out of that trend for the last 30 weeks. It is 63.4% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 30
Industry in uptrend
16% -15 in 4 wk
Insider buys, 12 months
$2.0M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
31 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 11 of 52 weeks.

20 Apr – 19 Oct
17%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$1.9MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months2
Sale orders, 12 months0
Buyers · sellers2 · 0
WhoDidSharesTraded
Orbimed Advisors Llc10% ownerbought597,729at $1.6716 Apr 2026filed 28 Apr 2026
Orbimed Advisors Llc10% ownerbought597,72916 Apr 2026filed 28 Apr 2026
Orbimed Advisors Llc10% ownerbought597,72916 Apr 2026filed 28 Apr 2026
Orbimed Advisors Llc10% ownerbought1,793,18716 Apr 2026filed 28 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders31+4 on the quarter
New · exited10 · 6
Reported value$5.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
ORBIMED ADVISORS LLCadded · filed 14 Aug 20261,203,260$1.0M+597,729+98.7%
Ally Bridge Group (NY) LLCnew · filed 14 Aug 2026786,236$663K+786,236
ADAGE CAPITAL PARTNERS GP, L.L.C.unchanged · filed 14 Aug 2026730,000$616K00.0%
ADAR1 Capital Management, LLCadded · filed 14 Aug 2026597,729$504K+443,631+287.9%
Lynx1 Capital Management LPadded · filed 12 Aug 2026559,470$472K+544,392+3610.5%
Ikarian Capital, LLCreduced · filed 14 Aug 2026478,142$403K-200,000−29.5%
SPHERA FUNDS MANAGEMENT LTD.new · filed 14 Aug 2026398,486$336K+398,486
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026330,049$278K+274,856+498.0%
JANE STREET GROUP, LLCadded · filed 14 Aug 2026216,006$182K+194,765+916.9%
Alyeska Investment Group, L.P.new · filed 14 Aug 2026164,376$139K+164,376
30 Sep 2024 – 30 Jun 2026
122130Sep 24Mar 25Sep 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Charles David Pauza Company insiderChief Science Officer Virology · last 9 Jul 20260 · 0
Charles Nolan Parker Company insiderChief Financial Officer · last 9 Jul 20260 · 0
Iain D. Dukes Company insiderChief Executive Officer · last 9 Jul 20260 · 0
Jack E. Stover Company insiderDirector · last 9 Jul 20261 · 0
John Harold Leaman Company insiderDirector · last 9 Jul 20260 · 0
Mary Teresa Shoemaker Company insiderDirector · last 9 Jul 20262 · 0
Nikolay Savchuk Company insiderChief Operating Officer · last 9 Jul 20260 · 0
Robert Redfield Company insiderChief Medical Officer · last 9 Jul 20260 · 0
Trafford Clarke Company insiderDirector · last 9 Jul 20260 · 0
Werner Cautreels Company insiderDirector · last 9 Jul 20260 · 0
ORBIMED ADVISORS LLC Company insider10% owner · last 16 Apr 20261 · 0
Orbimed Capital Gp Viii Llc Company insider10% owner · last 16 Apr 20261 · 0

Same industry

MRNA ModernaLeading+154%
ENTX Entera BioLeading+49%
XNCR XencorLeading+32%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2024 · to 31 Dec 2025-641%
Free cash flow marginFY 2024 · to 31 Dec 2025-744%
Cash conversionFY 2024 · to 31 Dec 2025-198%
Share count trendFY 2024 · to 13 Apr 202612.0%
Cash and equivalentsFY 2024 · to 31 Dec 2025$3.8M
Free cash flowFY 2024 · to 31 Dec 2025−$20.8M

Analyst forecasts

No analyst forecasts yet.